CyberKnife stereotactic radiosurgery for intracranial neoplasms, with a focus on malignant tumors.
Stereotactic radiosurgery is well established as a means of managing intracranial tumors, both as an adjuvant to surgical resection, and also as a primary treatment modality for those tumors that are considered unresectable by conventional surgical means. Of particular concern during radiosurgery of brain tumors is the risk of radiation damage to otherwise healthy tissue, potentially resulting in cognitive impairment. The conformality and precise targeting of the CyberKnife radiation beam enables this risk to be minimized to a greater extent than hitherto possible, which may allow treatment to be completed in a small number of fractions, thereby improving the quality of life for patients. The CyberKnife has proven particularly valuable in the treatment of metastases, which represent the great majority of brain tumors, though its role in the management of malignant glial tumors remains a subject of controversy. This article reviews the published studies on the efficacy of CyberKnife radiosurgery for brain tumors of both glial and metastatic origin, and considers its future role in the management of such lesions.